 | |
| Clinical data | |
|---|---|
| Other names | 2CT2-2EtO; 2-Ethoxy-4-ethylthio-5-methoxyphenethylamine |
| Routes of administration | Oral,intranasal[1] |
| Drug class | Serotonergic psychedelic;Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Onset of action | "Very quick"[1] |
| Duration of action | 5–9 hours[1] |
| Identifiers | |
| |
| PubChemCID | |
| Chemical and physical data | |
| Formula | C13H21NO2S |
| Molar mass | 255.38 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
2CT2-2-EtO, also known as2-ethoxy-4-ethylthio-5-methoxyphenethylamine, is apsychedelic drug of thephenethylamine,2C, andTWEETIO families related to2C-T-2.[1][2][3] It is thederivative of 2C-T-2 in which themethoxy group at the 2 position has been replaced with anethoxy group.[1][2][3]
According toAlexander Shulgin in his bookPiHKAL (Phenethylamines I Have Known and Loved) and other publications, 2CT2-2-EtO has a "completely effective" dose of 50 mgorally, a typical dose of 10 mgintranasally but with considerable variation between individuals, and aduration of 5 to 6 hours or of 9 hours.[1][2][3] Itsonset is said to be "very quick".[1] The effects of 2CT2-2EtO have been reported to includeblurred vision, intenseclosed-eye visuals, generation of a pleasant and contemplativemood,restlesssleep, andweird dreams.[1] Due to the large ~5-fold increase inpotency when taken intranasally instead of orally, 2CT2-2EtO may undergo substantialfirst-pass metabolism with oral administration.[3]
Thechemical synthesis of 2CT2-2-EtO has been described.[1]
2CT2-2-EtO was first described in the literature by Shulgin inPiHKAL in 1991.[1] It was developed and tested byDarrell Lemaire, with publication via personal communication with Shulgin.[2][4][5][6][7] The drug is acontrolled substance inCanada under phenethylamine blanket-ban language.[8]